The efficiency and safety of enisamium iodide and umifenoviri in ARVI treatment in real clinical practice

Background. Influenza and acute respiratory viral infection account for about 90% of all infectious morbidity in the population. Every year in Russia alone, from 27 to 41 million cases of these diseases are registered, and according to WHO, every adult on average gets sick with acute respiratory viral infection 2 to 4 times a year. Acute respiratory viral infection s are an etiologically heterogeneous group of infectious diseases affecting the respiratory tract, characterized by a relatively mild and short course. Today, specific antiviral drugs, including those against influenza, are widely represented on the pharmaceutical market. However, to date, no universal broad-spectrum antiviral agent has been created that can prevent the spread of acute respiratory viral infection. In this regard, the development of new antiviral drugs comes to the fore.

Objective. To evaluate the effectiveness and safety of antiviral drugs (enisamia iodide and umifenovir) in real clinical practice in patients with acute respiratory viral infection, with the exception of SARS-CoV-2.

Materials and methods. As part of the research work, 265 medical records of patients with infections caused by various pathogens of respiratory viral infections, with the exception of SARS-CoV-2. All medical records of patients were divided into 3 groups in accordance with the prescribed etiotropic therapy. The comparison group included patients who were not prescribed antiviral drugs. To study the effectiveness of the compared treatment regimens, we assessed the duration of hospitalization and the duration of the main clinical manifestations of acute respiratory viral infection, as well as the severity of the general infectious intoxication syndrome according to the anamnesis and the dynamics of the disease extracted from medical records.

Results. The duration of hospitalization of patients receiving antiviral therapy enisamia iodide was significantly less than that of patients receiving umifenovir (p < 0.05) and not receiving antiviral therapy. A significantly longer duration of fever was detected in the group of patients who did not receive antiviral therapy (p < 0.05). The duration of the main syndromes affecting the respiratory tract in patients from the group that did not receive etiotropic treatment was significantly longer (p < 0.05).

Conclusion. The drug enisamia iodide has been shown to have high therapeutic efficacy and a good safety profile. This allows us to consider it as a promising universal antiviral agent for the treatment of patients with influenza and acute respiratory viral infection (with the exception of SARS-CoV-2).

1. Ruuskanen O., Meurman O., Sarkkinen H. Adenoviral diseases in children: a study of 105 cases. Pediatrics. 1985; 76: 79-83.

2. Kasyanenko K. V., Kozlov K. V., Mal'tsev O. V., Lapikov I. I., Gordiyenko V. V., Sharabkhanov V. V., Sorokin P. V., Zhdanov K. V. Evaluation of the effectiveness of Riamilovir in complex therapy of patients with COVID-19. Terapevticheskiy arkhiv. 2021; 93 (3): 290-294. DOI: 10.26442/00403660.2021.03.200719. (In Russ.)

3. Lazareva N. B., Zhuravleva M. V., Panteleyeva L. R. ARVI: rational pharmacotherapy from the position of clinical pharmacology. Meditsinskiy sovet. 2016; 4: 68-73. (In Russ.)

4. Zarubayev V. V., Slita A. V., Sinegubova Ye. O. i dr. Antiviral activity of enisamium iodide against inf luenza and ARVI viruses in vitro on various cell lines. Terapevticheskiy arkhiv. 2020; 92 (11): 45-50. DOI: 10.26442/00403660.2020.11.000872. (In Russ.)

5. State register of medicines. Rezhim dostupa: https://grls.rosminzdrav.ru/. Ssylka aktivna na 10.11.2022. (In Russ.)

6. Payevskaya O. A., Zuyevskaya S. N., Nikiforov V. V. i dr. Possibilities of etiotropic therapy in reducing the risks of developing severe or complicated acute respiratory viral infections and influenza. RMJ. 2019; 1 (II): 77-80. (In Russ.)

7. Pshenichnaya N. Yu., Bulgakova V. A., Volchkova Ye. V. i dr. Review of current and promising areas of antiviral therapy for influenza and acute respiratory viral infections in Russia. Terapevticheskiy arkhiv. 2019; 91 (11): 105-109. DOI: 10.26442/00403660.2019.11.000454. (In Russ.)

8. Frolov A. F., Frolov V. M., Bukhtiarova T. A., Danilenko V. F. Clinical aspects of the use of Amizon. Meditsinskiy zhurnal. 2004; 39 (1): 69-74. (In Russ.)

9. Zyryanov S. K., Butranova O. I., Gayday D. S., Kryshen' K. L. Pharmacotherapy of acute respiratory infections caused by influenza viruses. Terapevticheskiy arkhiv. 2021; 93 (1): 114-124. (In Russ.)

10. Clinical guidelines "Acute respiratory viral infections in adults". Moskva, Natsional'naya assotsiatsiya spetsialistov po infektsionnym boleznyam imeni akademika V. I. Pokrovskogo (NASIB); Rossiyskoye nauchnoye meditsinskoye obshchestvo terapevtov (RMOT), 2023. (In Russ.)